首页> 外文期刊>肿瘤学与转化医学(英文) >The combined prognostic value of pretreatment neutrophil-to-lymphocyte ratio,lymphocyte-to-monocyte ratio,and platelet-to-lymphocyte ratio in stage IE/IIE extranodal natural killer/T-cell lymphoma
【24h】

The combined prognostic value of pretreatment neutrophil-to-lymphocyte ratio,lymphocyte-to-monocyte ratio,and platelet-to-lymphocyte ratio in stage IE/IIE extranodal natural killer/T-cell lymphoma

机译:IE / IIE结外自然杀手/ T细胞淋巴瘤的治疗前中性粒细胞与淋巴细胞比,淋巴细胞与单核细胞比,血小板与淋巴细胞比的联合预后价值

获取原文
获取原文并翻译 | 示例
       

摘要

Objective This study aimed to explore the combined prognostic value of pretreatment neutrophil-tolymphocyte ratio(NLR), lymphocyte-to-monocyte ratio(LMR), and platelet-to-lymphocyte ratio(PLR) in newly diagnosed IE/IIE extranodal natural killer/T-cell lymphoma(ENKTL) treated with a P-Gemox regimen combined with radiotherapy or radiotherapy alone.Methods A total of 132 patients from 2009 to 2017 at the Sichuan Cancer Hospital were enrolled in the study. The cutoff values of NLR, LMR, and PLR using overall survival(OS) rate as an endpoint were obtained by the receiver operating curve. Results The cutoff value of NLR was 3.5. Patients with high NLR had significantly shorter progressionfree survival(PFS)(P < 0.001) and OS(P < 0.001) than those with low NLR. Similarly, the cutoff value of LMR was 3.0. The high LMR group had significantly longer PFS(P=0.001) and OS(P < 0.001) than the low LMR group. Similarly, the cutoff value of PLR was 191.7. The high PLR group was significantly associated with poor PFS(P < 0.001) and OS(P < 0.001) than the low PLR group. Furthermore, combining NLR, LMR, and PLR to build a new model to stratify patients into low-, intermediate-, intermediate-high-, and high-risk groups, there were also significant differences in PFS(P < 0.001) and OS(P < 0.001). The univariate analysis showed that presenting B symptoms, stage IIE, local tumor invasion, Eastern Cooperative Oncology Group score ≥ 2, elevated lactate dehydrogenase level, elevated NLR, decreased LMR, and elevated PLR were significantly associated with poor survival. The multivariate analysis demonstrated that PLR was an independent prognostic factor for both PFS(hazard ratio [HR]= 2.073, 95% confidence interval [CI]= 1.080–3.981, P = 0.028) and OS(HR = 2.127, 95% CI = 1.102–4.107, P = 0.025).Conclusion Elevated pretreatment PLR was a novel simple predictor of poor survival in patients with stage IE/IIE ENKTL. Combining NLR, LMR, and PLR could provide additional stratification.
机译:目的探讨预处理中性粒细胞/淋巴细胞比(NLR),淋巴细胞/单核细胞比(LMR)和血小板/淋巴细胞比(PLR)在新诊断的IE / IIE淋巴结外自然杀手/中的联合预后价值方法:采用P-Gemox方案联合单纯放疗或放疗的T细胞淋巴瘤(ENKTL)。方法2009年至2017年在四川省肿瘤医院共纳入132例患者。以总生存(OS)率作为终点的NLR,LMR和PLR的临界值通过接收器工作曲线获得。结果NLR的截止值为3.5。高NLR患者的无进展生存期(PFS)(P <0.001)和OS(P <0.001)明显低于NLR低患者。同样,LMR的截止值为3.0。高LMR组的PFS(P = 0.001)和OS(P <0.001)比低LMR组更长。同样,PLR的截止值为191.7。与低PLR组相比,高PLR组与PFS差(P <0.001)和OS(P <0.001)显着相关。此外,结合NLR,LMR和PLR建立新模型以将患者分为低,中,中,高和高风险组,PFS(P <0.001)和OS( P <0.001)。单因素分析显示,表现为B症状,IIE分期,局部肿瘤浸润,东部合作肿瘤小组评分≥2,乳酸脱氢酶水平升高,NLR升高,LMR降低和PLR升高与不良的生存率显着相关。多元分析表明,对于PFS(危险比[HR] = 2.073,95%置信区间[CI] = 1.080–3.981,P = 0.028)和OS(HR = 2.127,95%CI =),PLR是一个独立的预后因素。 1.102–4.107,P = 0.025)。结论升高的治疗前PLR是IE / IIE ENKTL期患者生存不良的新型简单预测指标。将NLR,LMR和PLR结合使用可以提供更多分层。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号